Independent director

Sean P. Nolan

Independent Director·Ventas, Inc.

About

Sean P. Nolan is an Independent Director of Ventas (since 2019) and a member of the Compensation Committee and the Nominating, Governance and Corporate Responsibility Committee. He brings 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur.

Mr. Nolan previously served as CEO of AveXis, which he grew from four employees to a fully integrated global public company that was ultimately sold to Novartis for $8.7 billion.

Since 2019
Age 58
Tenure 7 yrs

Also at Ventas, Inc.

DC Debra A. Cafaro Chairman and Chief Executive Officer RP Robert F. Probst Executive Vice President and Chief Financial Officer PB Peter J. Bulgarelli Executive Vice President, Outpatient Medical and Research, Ventas, Inc.; President and CEO, Lillibridge Healthcare Services, Inc. JH J. Justin Hutchens Executive Vice President, Senior Housing and Chief Investment Officer CR Carey S. Roberts Executive Vice President, General Counsel, Ethics & Compliance Officer and Corporate Secretary GL Gregory R. Liebbe Senior Vice President, Chief Accounting Officer and Controller

Roles

Organization Role Dates Details
Ventas, Inc. Independent Director 2019–present Current role
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) Chief Executive Officer (since 2022); Chairman of the Board (since 2020)
Nolan Capital, LLC President An investment fund (since 2019).
AveXis, Inc. (formerly NASDAQ: AVXS) President and Chief Executive Officer 2015-2018 Gene therapy company sold to Novartis for $8.7 billion.
InterMune, Inc. (formerly NASDAQ: ITMN) Chief Business Officer 2013-2015 Biopharmaceutical company.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Chief Commercial Officer 2011-2012 Pharmaceuticals company.
Lundbeck, Inc. Chief Commercial Officer and President 2009-2010 U.S. affiliate of H. Lundbeck A/S, a Danish pharmaceuticals company.

External roles

Organization Role Dates
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) Director / Chairman of the Board
Neoleukin Therapeutics (now Neurogene, Inc.) (NASDAQ: NLTX) Director 2019-2020
Aquinox Pharmaceuticals, Inc. (formerly NASDAQ: AQXP) Director 2015-2019

Related

Company Ventas, Inc. Company hub Person Debra A. Cafaro Chairman and Chief Executive Officer Person Robert F. Probst Executive Vice President and Chief Financial Officer Person Peter J. Bulgarelli Executive Vice President, Outpatient Medical and Research, Ventas, Inc.; President and CEO, Lillibridge Healthcare Services, Inc. Person J. Justin Hutchens Executive Vice President, Senior Housing and Chief Investment Officer Person Carey S. Roberts Executive Vice President, General Counsel, Ethics & Compliance Officer and Corporate Secretary Person Gregory R. Liebbe Senior Vice President, Chief Accounting Officer and Controller Person Kevin M. Bohl Senior Vice President, Deputy General Counsel and Assistant Corporate Secretary (interim General Counsel, Ethics & Compliance Officer and Corporate Secretary as of June 26, 2026) Person Melody C. Barnes Independent Director Person Theodore R. Bigman Independent Director Person Debra A. Cafaro (Director) Chairman and CEO (Director) Person Michael J. Embler Independent Director Person Matthew J. Lustig Independent Director Deal Ventas American Realty Capital Healthcare Trust Hct 2015 Deal page Deal Ventas Ardent Health Services Ardent Medical Services 2015 Deal page Deal Ventas Atria Senior Living Real Estate Assets 2011 Deal page
Source: Ventas, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo